These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18236358)

  • 21. Rosiglitazone--continued uncertainty about safety.
    Drazen JM; Morrissey S; Curfman GD
    N Engl J Med; 2007 Jul; 357(1):63-4. PubMed ID: 17551160
    [No Abstract]   [Full Text] [Related]  

  • 22. PROactive study.
    Guillausseau PJ
    Lancet; 2006 Jan; 367(9504):23; author reply 26-7. PubMed ID: 16399140
    [No Abstract]   [Full Text] [Related]  

  • 23. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
    Kaul S; Bolger AF; Herrington D; Giugliano RP; Eckel RH; ;
    J Am Coll Cardiol; 2010 Apr; 55(17):1885-94. PubMed ID: 20413044
    [No Abstract]   [Full Text] [Related]  

  • 24. Pioglitazone is a valid alternative to rosiglitazone.
    Derosa G
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):357-62. PubMed ID: 21950735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rosiglitazone and cardiovascular risk.
    Mannucci E; Monami M; Marchionni N
    N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
    [No Abstract]   [Full Text] [Related]  

  • 26. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
    Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
    [No Abstract]   [Full Text] [Related]  

  • 27. [The benefit of pioglitazone in patients with diabetes mellitus type 2 and cardiovascular complications].
    Olsovský J
    Vnitr Lek; 2005 Dec; 51(12):1412. PubMed ID: 16430111
    [No Abstract]   [Full Text] [Related]  

  • 28. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 29. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.
    Schernthaner G; Currie CJ; Schernthaner GH
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S155-61. PubMed ID: 23882041
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular effects of thiazolidinediones: a review of the literature.
    Acharya D; Falik R
    South Med J; 2009 Jan; 102(1):51-6. PubMed ID: 19077768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thiazolidinediones.
    Mascitelli L; Pezzetta F
    N Engl J Med; 2005 Jan; 352(2):205-7; author reply 205-7. PubMed ID: 15651125
    [No Abstract]   [Full Text] [Related]  

  • 32. [Rosiglitazone].
    Johansen K
    Ugeskr Laeger; 2010 Sep; 172(38):2631; author reply 2631. PubMed ID: 20931733
    [No Abstract]   [Full Text] [Related]  

  • 33. A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.
    Krumholz HM
    Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):221-2. PubMed ID: 20181986
    [No Abstract]   [Full Text] [Related]  

  • 34. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 35. Diabetes: Breaking news! Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Nat Rev Cardiol; 2010 Dec; 7(12):670-2. PubMed ID: 21102630
    [No Abstract]   [Full Text] [Related]  

  • 36. Diabetes drug safety update: Avandia and your heart.
    Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
    [No Abstract]   [Full Text] [Related]  

  • 37. Rosiglitazone and cardiovascular risk.
    Bracken MB
    N Engl J Med; 2007 Aug; 357(9):937-8; author reply 939-40. PubMed ID: 17761600
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA committee urges tight restrictions on rosiglitazone.
    Roehr B
    BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
    [No Abstract]   [Full Text] [Related]  

  • 39. PROactive in patients with type 2 diabetes and previous myocardial infarction: swinging the sword of Damocles?
    Westerbacka J
    J Am Coll Cardiol; 2007 May; 49(17):1781-2. PubMed ID: 17466228
    [No Abstract]   [Full Text] [Related]  

  • 40. Effectiveness and side effects of thiazolidinediones for type 2 diabetes.
    Arnold N; McLean M; Chipps DR; Cheung NW
    Med J Aust; 2005 May; 182(9):494. PubMed ID: 15999431
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.